FGFR4-IN-1 Selective Inhibitor: Properties, Use & Protocol

FGFR4-IN-1 is a selective small-molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4) used as a research tool to dissect FGFR4-driven signaling pathways in cancer biology and related disease models.

Product Name

FGFR4-IN-1

SKU

F656083

Primary Target

FGFR4 (Fibroblast Growth Factor Receptor 4)

Compound Class

Selective small-molecule kinase inhibitor

Reference Catalog

MCE HY-100631

Recommended Storage

-20 °C, protected from light and moisture (verify with CoA)

Typical Solvent

DMSO (verify solubility with CoA before use)

What Is FGFR4-IN-1?

FGFR4-IN-1 is a selective inhibitor targeting fibroblast growth factor receptor 4 (FGFR4), a receptor tyrosine kinase belonging to the FGFR family (FGFR1–4). FGFR4 plays a distinct physiological role in bile acid synthesis, hepatic glucose and lipid metabolism, and has been implicated as an oncogenic driver in hepatocellular carcinoma, breast cancer, rhabdomyosarcoma, and other solid tumors. Selective inhibition of FGFR4, rather than pan-FGFR inhibition, is of significant research interest because it may reduce the on-target toxicities (such as hyperphosphatemia) associated with broad FGFR blockade. FGFR4-IN-1 is catalogued under Aladdin Scientific SKU F656083 and is cross-referenced to MCE catalog number HY-100631.

Selectivity Profile and Mechanism of Action

FGFR4-IN-1 is designed to selectively inhibit FGFR4 kinase activity over the closely related family members FGFR1, FGFR2, and FGFR3. Selectivity within the FGFR family is pharmacologically challenging due to high sequence homology in the kinase domain; FGFR4-IN-1 achieves selectivity partly by exploiting a unique cysteine residue (Cys552) in the FGFR4 ATP-binding site that is absent in FGFR1–3, enabling covalent or covalent-like interactions depending on inhibitor design. By suppressing FGFR4 kinase activity, FGFR4-IN-1 blocks downstream signaling cascades including the RAS/MAPK, PI3K/AKT, and STAT3 pathways, thereby reducing proliferation and survival signals in FGFR4-dependent cell lines. Researchers should confirm the precise IC50 values and selectivity panel data for their specific lot from the certificate of analysis (CoA) or peer-reviewed literature, as exact figures are not independently verified in this guideline.

Preparation and Handling Protocol

Stock Solution Preparation: FGFR4-IN-1 is typically soluble in dimethyl sulfoxide (DMSO). To prepare a stock solution, weigh the required amount of compound and dissolve in an appropriate volume of DMSO to achieve the desired concentration (commonly 10–50 mM). Vortex thoroughly and sonicate briefly if needed to ensure complete dissolution. Verify the exact solubility limit from the product CoA before preparation.

Working Solution Preparation: Dilute the DMSO stock into aqueous cell culture medium or assay buffer immediately before use. Ensure that the final DMSO concentration does not exceed 0.1–0.5% (v/v) in cell-based assays to avoid solvent-induced cytotoxicity. Include vehicle-only controls in all experiments.

Storage: Store lyophilized or solid compound at −20 °C, desiccated and protected from light. DMSO stock solutions may be aliquoted and stored at −20 °C; avoid repeated freeze–thaw cycles. Confirm storage conditions on the product CoA, as individual lot requirements may vary.

Safety: Handle in accordance with standard laboratory chemical safety guidelines. Wear appropriate PPE (gloves, lab coat, eye protection). Consult the Safety Data Sheet (SDS) for specific hazard information.

Research Applications

FGFR4-IN-1 is employed as a pharmacological tool compound in a variety of research contexts:

• Cancer Biology: Investigators use FGFR4-IN-1 to validate FGFR4 as a therapeutic target in FGFR4-amplified or FGF19-overexpressing hepatocellular carcinoma models and other FGFR4-driven tumors.
• Signaling Pathway Studies: The compound helps delineate FGFR4-specific contributions to RAS/MAPK, PI3K/AKT, and JAK/STAT signaling, particularly in contexts where pan-FGFR inhibitors cannot distinguish receptor-subtype contributions.
• Combination Studies: FGFR4-IN-1 may be combined with other targeted agents (e.g., MEK, AKT, or checkpoint inhibitors) to assess synergistic effects in preclinical models.
• In Vitro Assays: Suitable for kinase activity assays, cell viability assays, western blotting for phospho-FGFR4 and downstream markers, and flow cytometry-based apoptosis studies.
• Metabolic Research: Given FGFR4's role in bile acid and lipid metabolism, FGFR4-IN-1 can be applied in hepatic metabolic studies to probe receptor function.

This compound is intended for research use only and is not approved for human therapeutic use.

Quality, Purity and Regulatory Considerations

Aladdin Scientific supplies FGFR4-IN-1 (SKU F656083) as a research-grade reagent. Each lot is accompanied by a Certificate of Analysis (CoA) specifying purity (typically assessed by HPLC), identity confirmation (NMR, MS or equivalent), and physical data. Researchers should:

• Download and review the CoA for the specific lot received prior to experimental use.
• Verify purity is appropriate for the intended application; for highly quantitative assays, higher purity grades may be required.
• Note that this product is for research use only (RUO) and is not intended for diagnostic, therapeutic, or veterinary use.
• Comply with all applicable institutional, local, and national regulations regarding the use, storage, and disposal of chemical reagents.
• Consult the SDS for waste disposal and spill response procedures.

Frequently asked questions

What is FGFR4-IN-1 and what does it inhibit?

FGFR4-IN-1 is a selective small-molecule inhibitor designed to target fibroblast growth factor receptor 4 (FGFR4), a receptor tyrosine kinase implicated in cancer and metabolic regulation. It suppresses FGFR4 kinase activity with selectivity over related FGFR family members, making it a useful tool compound for studying FGFR4-specific biology.

How should I prepare a stock solution of FGFR4-IN-1?

FGFR4-IN-1 is typically dissolved in DMSO to prepare a concentrated stock solution (commonly 10–50 mM). Vortex and briefly sonicate to ensure complete dissolution. Always verify the exact solubility limit and recommended concentration from the product Certificate of Analysis before use, and aliquot stocks to avoid repeated freeze–thaw cycles.

What cancer types is FGFR4 most relevant to in research?

FGFR4 has been most extensively studied in hepatocellular carcinoma (HCC), particularly in tumors with FGF19 amplification or overexpression, which drives autocrine FGFR4 signaling. It is also investigated in rhabdomyosarcoma, breast cancer, and other solid tumors. FGFR4-IN-1 is commonly used in these research contexts to validate FGFR4 as a therapeutic target.

What controls should I include when using FGFR4-IN-1 in cell-based assays?

Always include a vehicle control (DMSO at the same final concentration as the inhibitor-treated wells), an untreated control, and where possible a positive control using a validated pan-FGFR or FGFR4-selective inhibitor with known activity. This allows discrimination of compound-specific effects from solvent cytotoxicity and confirms assay performance.

Is FGFR4-IN-1 suitable for in vivo studies?

While FGFR4-IN-1 is primarily characterized as an in vitro tool compound, its suitability for in vivo use depends on its pharmacokinetic properties such as bioavailability, metabolic stability, and tolerability. Researchers should consult the primary literature and perform appropriate formulation and PK studies before using FGFR4-IN-1 in animal models. Specific in vivo data for this compound should be verified from peer-reviewed sources.

References

1. Kang HJ et al. Selective FGFR4 inhibition research — see primary literature for compound HY-100631/FGFR4-IN-1. Note: specific citation not independently verified; flag for review.
2. MCE (MedChemExpress) Product Page for HY-100631 (FGFR4-IN-1). Cross-reference to Aladdin SKU F656083. Accessed via supplier documentation.
3. Hagel M et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 2015 — specific author list and title require verification against PubMed.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.